{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Beck M"],"funding":["AstraZeneca","Friedrich-Alexander-Universität Erlangen-Nürnberg"],"pagination":["623-633"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9226092"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["36(7)"],"pubmed_abstract":["Aim
In the CheckRad-CD8 trial patients with locally advanced head and neck squamous cell cancer are treated with a single cycle of induction chemo-immunotherapy (ICIT). Patients with pathological complete response (pCR) in the re-biopsy enter radioimmunotherapy. Our goal was to study the value of F-18-FDG PET/CT in the prediction of pCR after induction therapy.Methods
Patients treated within the CheckRad-CD8 trial that additionally received FDG- PET/CT imaging at the following two time points were included: 3-14 days before (pre-ICIT) and 21-28 days after (post-ICIT) receiving ICIT. Tracer uptake in primary tumors (PT) and suspicious cervical lymph nodes (LN +) was measured using different quantitative parameters on EANM Research Ltd (EARL) accredited PET reconstructions. I"],"journal":["Annals of nuclear medicine"],"pubmed_title":["F18-FDG PET/CT imaging early predicts pathologic complete response to induction chemoimmunotherapy of locally advanced head and neck cancer: preliminary single-center analysis of the checkrad-cd8 trial."],"pmcid":["PMC9226092"],"funding_grant_id":["ESR-16-12356"],"pubmed_authors":["Hecht M","Klautke G","Beck M","Muller S","Kuwert T","Hartwich J","Hartmann A","Schmidt D","Gaipl US","Hautmann MG","von der Grun J","Brunner T","Rutzner S","Doscher J","Illmer T","Iro H","Fietkau R","Semrau S","Eckstein M","Tamaskovics B","Gostian AO"],"additional_accession":[]},"is_claimable":false,"name":"F18-FDG PET/CT imaging early predicts pathologic complete response to induction chemoimmunotherapy of locally advanced head and neck cancer: preliminary single-center analysis of the checkrad-cd8 trial.","description":"Aim
In the CheckRad-CD8 trial patients with locally advanced head and neck squamous cell cancer are treated with a single cycle of induction chemo-immunotherapy (ICIT). Patients with pathological complete response (pCR) in the re-biopsy enter radioimmunotherapy. Our goal was to study the value of F-18-FDG PET/CT in the prediction of pCR after induction therapy.Methods
Patients treated within the CheckRad-CD8 trial that additionally received FDG- PET/CT imaging at the following two time points were included: 3-14 days before (pre-ICIT) and 21-28 days after (post-ICIT) receiving ICIT. Tracer uptake in primary tumors (PT) and suspicious cervical lymph nodes (LN +) was measured using different quantitative parameters on EANM Research Ltd (EARL) accredited PET reconstructions. I","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2025-06-01T02:05:23.257Z","creation":"2025-06-01T02:05:23.257Z"},"accession":"S-EPMC9226092","cross_references":{"pubmed":["35534690"],"doi":["10.1007/s12149-022-01744-6"]}}